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Background: The efficiency of CD4/CCR5 mediated HIV-1 entry has important implications for pathogenesis and
transmission. The HIV-1 receptor affinity profiling (Affinofile) system analyzes and quantifies the infectivity of HIV-1
envelopes (Envs) across a spectrum of CD4/CCR5 expression levels and distills these data into a set of Affinofile
metrics. The Affinofile system has shed light on how differential CD4/CCR5 usage efficiencies contributes to an array
of Env phenotypes associated with cellular tropism, viral pathogenesis, and CCR5 inhibitor resistance. To facilitate
more rapid, convenient, and robust analysis of HIV-1 entry phenotypes, we engineered a reporter Affinofile system
containing a Tat- and Rev-dependent Gaussia luciferase-eGFP-Reporter (GGR) that is compatible with the use of
pseudotyped or replication competent viruses with or without a virally encoded reporter gene. This GGR Affinofile
system enabled a higher throughput characterization of CD4/CCR5 usage efficiencies associated with differential
Env phenotypes.
Results: We first validated our GGR Affinofile system on isogenic JR-CSF Env mutants that differ in their affinity for
CD4 and/or CCR5. We established that their GGR Affinofile metrics reflected their differential entry phenotypes
on primary PBMCs and CD4+ T-cell subsets. We then applied GGR Affinofile profiling to reveal distinct entry
phenotypes associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies
(BNAbs). First, we profiled a panel of reference subtype B transmitted/founder (T/F) and chronic Envs (n = 12) by
analyzing the infectivity of each Env across 25 distinct combinations of CD4/CCR5 expression levels. Affinofile
metrics revealed that at low CCR5 levels, our panel of subtype B T/F Envs was more dependent on high levels of
CD4 for HIV-1 entry compared to chronic Envs. Next, we analyzed a reference panel of 28 acute/early subtype A-D
Envs, and noted that subtype C Envs could be distinguished from the other subtypes based on their infectivity
profiles and relevant Affinofile metrics. Lastly, mutations known to confer resistance to VRC01 or PG6/PG19 BNAbs,
when engineered into subtypes A-D Envs, resulted in significantly decreased CD4/CCR5 usage efficiency.
Conclusions: GGR Affinofile profiling reveals pathophysiological phenotypes associated with varying HIV-1 entry
efficiencies, and highlight the fitness costs associated with resistance to some broadly neutralizing antibodies.
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Human immunodeficiency virus type 1 (HIV-1) enters tar-
get cells through the stepwise interaction of its envelope
glycoproteins (Env) with CD4 and a coreceptor, either
CCR5 or CXCR4. Receptor binding induces a series of
conformational changes that results in fusion pore forma-
tion and virus/cell membrane fusion [1]. Acutely transmit-
ted viruses invariably use CCR5 (R5) regardless of the
subtype. Furthermore, although CXCR4-using (X4, R5X4)
viruses can emerge in approximately 40-50% of late stage
HIV-1 subtype B infections [2,3], most HIV-1 infected
subjects, particularly those with subtype A and C viruses
[4-6], progress to late stages of infection despite exclu-
sively harboring R5 viruses.
While many viral and host factors contribute to HIV-1
progression, there is a strong body of evidence that sup-
ports some Env determinants of pathogenicity. For ex-
ample, in patients with R5 viruses, isolates from late
stages of infection have a greater capacity to infect macro-
phages [7-9], which correlates with more efficient usage of
the low levels of CD4 and CCR5 expressed on these cells
[9-13]. These late stage R5 isolates can also cause in-
creased levels of cell-cell fusion [14] and CD4+ T-cell
apoptosis [15]. Late stage brain isolates have also been
shown to utilize low levels of CD4 and/or CCR5 for entry
[16-24]. Therefore, viruses capable of exploiting limiting
levels of CD4 and/or CCR5 may have expanded target cell
tropism with pathological consequences [24-26]. Further-
more, viruses that are resistant to the CCR5 antagonists
vicriviroc (VVC) and maraviroc (MVC) exhibit a reduced
ability to use lower levels of CCR5 compared to their
non-resistant counterparts [27-29]. Finally, the recent
characterization of transmitter/founder (T/F) Envs has
indicated that these R5 variants enter and replicate in
activated primary T-cells but not macrophages [30],
underscoring the increasingly evident notion that CCR5
usage is not equivalent to macrophage-tropism [5,31].
Together, these studies show that the efficiency with
which a viral Env engages CD4 and/or CCR5 can have
an influence on pathogenicity, disease progression and
resistance to CCR5 antagonists [5,32,33]. Therefore, a
more refined understanding of how Env-CD4/CCR5
usage develops and differs under alternate evolutionary
histories will inform the development and use of HIV-1
vaccines and therapeutics that target HIV-1 entry.
The Affinofile system, based on a CD4 and CCR5 dual-
inducible cell line, permits quantitative characterization of
HIV-1 infection across 24–48 distinct combinations of
CD4/CCR5 expression levels [34]. Multiple groups have
used this receptor affinity profiling system (Affinofile) to
reveal unique CD4/CCR5 usage efficiencies associated
with distinct pathophysiological phenotypes. These studies
have shed light on the nature of CCR5-inhibitor resistance
[27-29,35-37], the relationship between CD4/CCR5 usageand cellular tropism as well as disease pathogenesis [38],
and CD4/CCR5 usage interdependence (reviewed in [39]).
Using this system, the infectivity of an Env under 24–48
distinct combinations of CD4 and CCR5 expression is
compiled and summarized as three metrics that collect-
ively describe a distinct profile of CD4 and CCR5 usage.
Biological insights are gained by comparing the Affinofile
metrics of different Envs. Affinofile metrics can be ex-
tracted from infectivity data by an automated web-based
computational platform [34].
Comprehensive infectivity profiling requires the exam-
ination of each Env under multiple distinct combina-
tions of CD4/CCR5 expression levels. To gain further
insights into HIV-1 entry phenotypes associated with
distinct pathophysiologies, and to examine a larger panel
of Envs from distinct cohorts, we engineered a higher
throughput, second generation Affinofile system that
would: (1) improve the robustness of the infectivity data
obtained, (2) ease the process of data sampling and ana-
lysis by permitting sequential time-point sampling of the
infected cell supernatant without the need for end-point
lysis, and (3) allow infectivity measurements without re-
quiring a virus-associated reporter gene while retaining
compatibility with any HIV-1 proviral backbone used for
Env pseudo typing. To this end, we transduced Affinofile
cells with a Tat- and Rev-dependent reporter engineered
to express green fluorescent protein (GFP) and secrete
Gaussia luciferase into the supernatant upon infection.
This Gaussia luciferase-GFP reporter (GGR) Affinofile
cell line now permits simple and rapid detection of HIV-
1 infection by serial sampling a small volume of super-
natant for Gaussia luciferase activity, while also taking
full advantage of the CD4 and CCR5 inducibility of the
original Affinofile cells.
In this study, we validate our new GGR Affinofile sys-
tem, and use this improved, higher throughput GGR
Affinofile system to reveal distinct Env phenotypes asso-
ciated with acute transmission, subtype specificity and
neutralization resistance.
Results
Generation and characterization of the GGR Affinofile
cell line
We modified a previously published Tat/Rev-dependent
vector [40,41] by cloning the Gaussia luciferase (GLuc)
gene upstream of an eGFP reporter gene, linked via an
internal ribosomal entry site (IRES) (Figure 1A). Judi-
ciously placed splice donor and acceptor sites, in addition
to the Rev-responsive element (RRE) placed downstream
of the eGFP reporter gene, ensures that only the full-
length, unspliced reporter mRNA will be translated in the
presence of Tat and Rev, which is provided by commonly
used HIV-1 reporter vectors and replication-competent

















































































Transport of fully spliced mRNA
Minimal G.Luc or GFP expression
Increased mRNA transcription due to HIV Tat
Transport of unspliced mRNA by HIV Rev
Maximal G.Luc or GFP expression
Figure 1 Generation and characterization of the GGR Affinofile Cell Line. (A) Schema of the tat-rev dependent Gaussia luciferase (gLuc)-
IRES-GFP reporter vector as described in the text. (B) and (C) GGR cells were maximally induced with doxycyline (Doxy, 4ng/ml) and ponasterone
A (PonA, 4 μM) at the time of their seeding in 96-well plates. 16–21 hours post-seeding/induction, cells were infected with wt JR-CSF virus at
varying multiplicities of infection (MOI). The titer of the virus was previously determined on stable CD4/CCR5-expressing GHOST cells where CD4/
CCR5 levels are non-limiting. At 17, 24, 48, and 72 hpi, 10 μL (out of 150) of the infected cell supernatant was removed and analyzed for gLuc
activity as per manufacturer’s instructions. Luciferase activity (measured as relative light units, RLU), and the corresponding signal:noise ratios at
each data point are shown in (B) and (C), respectively. Mock-infected cell supernatant served as the background signal. (D) and (E) GGR cells
were induced at high (3.2ng/mL Doxy, 2 μM PonA), medium (1.6ng/mL Doxy, 1μm PonA), and low (0.4ng/mL Doxy, 0.25μM PonA) levels, and
infected as above with pseudotyped virus at an MOI of 0.25. Three days post-infection, supernatant was collected and analyzed for gluc expression (E),
while cells from each well were individually processed for intracellular p24 staining (D) as described in methods. Data shown is representative of two
independent experiments.
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duce early passage Affinofile cells. Stable GGR Affinofile
cell lines with optimal properties were single cell cloned
as described in methods.
To determine the ability of GGR Affinofile cells to de-
tect HIV-1 infection, we infected a stable clone of GGRAffinofile cells (at maximum CD4/CCR5 induction)
using a range of viral inoculums (JR-CSF, MOI = 0.5 –
0.0625) and serially sampled the infected cell culture
supernatant for GLuc activity. GLuc activity could be de-
tected at 20-fold above background as early as 17 hpi
depending on the amount of viral inoculum used
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tivity in the infected culture supernatant mirrored the
level of infection as reported by intracellular p24 stain-
ing (Figure 1D-E), especially at low MOIs (e.g. 0.2) that
ensure a single infectious event per cell.
Defining the parameters that impact the infectivity
metrics used for profiling HIV-1 entry efficiency
We previously demonstrated that R5 virus infection of
Affinofile cells across a spectrum of CD4 and CCR5 ex-
pression levels generated an infectivity profile (Figure 2A)A B 
The surface function F(x, y) is the best-fit surface p
at varying levels of CD4 and CCR5.  
The mean infectivity, M, provides a rough estima
normalized function F(x, y) across the entire range
represented by the x-y plane.    
The gradient of F(x, y)  is represented by a sensiti
vector has two metrics: theta ( ): the angle of the 
the magnitude or steepness of that gradient. 
The angle of the sensitivity vector (theta, ) me
responsive to changes in cell surface levels of CD4
y-axis).  











Figure 2 Defining the limiting parameters of sensitivity vector metric
primary subtype B R5-virus monitored across 25 distinct combinations of C
shown as a 3-D bar graph with the luciferase activity obtained at the highe
function F(x, y) is used to fit the infectivity data as previously described [34
that reflect distinct phenotypic properties of the infecting virus envelope: (
(Δ) of the sensitivity vector S
⇀
that describes the envelope’s response to var
these metrics, and what they measure with respect to the infectious pheno
nomenclature of these Affinofile metrics to more intuitively reflect the Env
are the same as in Johnston et al. (Ref [34]). Thus, “mean induction” is now
vector “amplitude”.that can be fitted by the surface function F(x, y) to give
the surface plot shown in Figure 2B. F(x, y) describes the
infectivity response as a function of CD4 and CCR5 cell
surface expression levels [34]. The salient features of this
surface function can be captured by three biophysically
meaningful parameters illustrated in Figure 2B and C:
the mean infectivity level M (Figure 2B), and the angle
and amplitude of the sensitivity vector (S
⇀
) representing
the gradient of the surface function F(x, y) on a 2-D plot
(Figure 2C). Mean infectivity (M) expresses the overall
infectivity observed across all levels of CD4 and CCR5C 
lot that describes the relative infectivity of an envelope 
te of the overall entry efficiency; it is the mean of the 
 of CD4 (x) and CCR5 (y) surface expression levels 
vity vector in the 2-D plot shown in Fig. 2C.  The 
gradient path relative to the CD4 axis; and Delta ( ): 
asures whether the infectivity of a given Env is more 
 (as x-axis) or CCR5 (as 
) measures the amplitude of infectivity response along 
F(x, y) gradient, complementing the angle of this path 
s used for profiling HIV-1 entry efficiency. (A) Infectivity of a
D4 and CCR5 expression levels. The normalized infectivity profile is
st CD4 and CCR5 induction level set at 100%. (B-C) The surface
]. The resulting 3-D surface plot can be represented by three metrics
B) the mean infectivity level (M), and (C) the angle (θ) and amplitude
ying levels of CD4 and CCR5. For clarity, the operational definitions of
type of Env, are also indicated. Note that while we have changed the
properties they are intended to describe, the fundamental definitions
termed “mean infectivity”, and vector “magnitude” is now termed
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vector ( S
⇀
) shown in Figure 2C, representing both the
stoichiometric combination of CD4 and CCR5 with the
greatest impact on entry across the entire surface (θ)
and the magnitude of that impact (Δ) illustrated by the
vector field in Figure 2C. For example, a relative increase
in θ, driven by a shift in the gradient toward the CCR5
axis (Figure 2C), indicates a greater responsiveness to
CCR5. The magnitude of this shifted responsiveness may
be comparatively larger (increased Δ) or smaller (de-
creased Δ), indicating a relative increase in CCR5 usage
efficiency or a decrease in both CD4 and CCR5 usage ef-
ficiency, respectively. The operational definitions of these
parameters are indicated in the panels below Figure 2A-C.
Their mathematical definitions and formulations have
been reviewed recently [39]. Together, these three metrics
quantitatively describe the phenotypic behavior of a given
viral envelope in response to changes across a spectrum of
CD4 and CCR5 expression levels.
Similar to regular Affinofile cells, GGR Affinofile cells
can be used to characterize a range of distinct Env pheno-
types (see Additional file 1: Figure S1A-C) and the infect-
ivity profile of each Env can be represented by the set of
three metrics (Additional file 1: Figure S1D-F). Notably,
all three metrics (θ, Δ, M) for a given Env can be repre-
sented on a polar plot and are highly reproducible under
standardized conditions (Additional file 1: Figure S1G).Affinofile metrics illuminate the phenotype of functionally
well-characterized point mutants
To further define the biological meaning of the three
Affinofile metrics, we examined three point mutants in
JR-CSF with well-described effects on CD4 and CCR5
binding. S142N [42] and E153G [43] are both V1 loop
mutations that increase the ability of JR-CSF to enter
cells with low levels of CCR5 [20,25] or CD4, respect-
ively, while K421D is a “bridging sheet” mutant that re-
duces the affinity of gp120 for CCR5 [44,45]. Viruses
pseudotyped with wild type (wt) JR-CSF, or with S142N
or K421D Env mutants were produced and titrated first
on Ghost-R5 cells. An equivalent MOI (0.2) of each
pseudotype was then used to infect GGR Affinofile cells
expressing 25 distinct combinations of CD4 and CCR5
levels. We are cognizant that viral titers are cell-type
dependent, but we reasoned that normalizing the infec-
tious inoculum on GGR Affinofile cells using titers ob-
tained from infecting Ghost-R5 cells (where CD4/CCR5
levels are non-limiting) would fairly reveal biologically
relevant differences in entry efficiencies when CD4/CCR5
levels do become limiting under certain induction condi-
tions on GGR Affinofile cells.
Compared to wt JR-CSF (Figure 3A), the S142N mu-
tant exhibited enhanced entry at every level of CCR5 ator above a specific threshold level of CD4 (0.4 ng/ml
Doxy) (Figure 3B, compare the rows of green, yellow, or-
ange and red bars along the CCR5 axis with Figure 3A).
A similar increase in infection was observed for E153G,
particularly at low CD4 expression (compare blue and
green bars in Figure 3C to A), whereas the K421D mu-
tant showed inefficient entry at low CCR5 levels regard-
less of how much CD4 was present (Figure 3D, note the
low infectivity at 0 and 0.25 μM PonA (<20% of max-
imum) even when CD4 was maximally induced). S142N
was more responsive to changes in CCR5 levels than wt
JR-CSF, and this phenotype was reflected as an increase
in from 30.5° to 38° for wt JR-CSF and S142N, respect-
ively. Recall that a relative increase or decrease in vector
angle indicates that an Env’s infectivity is more responsive
to changes in levels of CCR5 or CD4, respectively. A sum-
mary of the Affinofile metrics is given in Figure 3E, and il-
lustrated in the polar plots below Figures 3A-D.
For S142N, the ability to use CCR5 efficiently also en-
hanced its infectivity at any given level of CD4; thus, the
overall level of infection across the entire matrix of
CD4/CCR5 expression is higher. This overall increase in
infectivity is reflected in the increase in M from 20 to
40.3 for wt JR-CSF and S142N, respectively (Figure 3E,
and also graphically represented by the size of the circle
in the polar plot below Figure 3B). This combination of
an increase in θ and M support the conclusion that
S142N uses CCR5 more efficiently.
E153G, which putatively confers the ability to use low
levels of CD4, also exhibited an increased M (32.1) com-
pared to wt JR-CSF (20.1), illustrating that these muta-
tions, both attributed to usage of low CD4 or CCR5
expression, have a broad impact on infectivity across all
combinations of CD4 and CCR5. This highlights the
inter-dependence of CD4 and CCR5 usage as, for ex-
ample, a higher CD4 binding affinity is likely to increase
the success of gp120-CCR5 engagement. E153G exhib-
ited a stronger response to CCR5 expression than CD4
compared to wt JR-CSF, which is reflected in an in-
creased angle (38°, Figure 3E), matching the same re-
sponsive phenotype observed for S142N. That E153G
would necessarily result in a lower, or more CD4-
responsive, angle than wt JR-CSF or S142N is not obvi-
ous given the proposed indirect mechanism by which
this mutation primes Env to use low levels of CD4.
E153G is positioned distal to the CD4 binding site at the
apex of the Env trimer and also results in a higher
neutralization sensitivity to the V3 loop conformational
Mab 447-52D [43]. Our data supports the conclusion of
Clapham and colleagues, that the ability to use low levels
of CD4 attributed to E153G is not the direct result of
CD4 engagement, but the result of a more fluid and suc-
cessful transition to CCR5 recognition due to the muta-
tion’s effect on V1/V2 mobility [43]. These results
Figure 3 Sensitivity vector metrics further illuminate the phenotype of well-characterized point mutants. (A) Infectivity profile of wt
JR-CSF (R5) envelope, and three point mutants: (B) S142N, (C) E153G and (D) K421D, previously shown to enhance or perturb CCR5 or CD4 usage
with polar plots (beneath) representing the metrics obtained from mathematical analysis of the infectivity profiles (A-C). The vector angle (θ) is
the angle between the x-axis and the dotted line. The vector amplitude (Δ) is represented by the length of the dotted line. The mean infectivity
(M) is represented by the size of the circle. Data shown is a representative of two experiments. (E) Table of the average Affinofile metrics obtained
from (A-D) and graphically shown in polar plots beneath (A-D). Boxes next to (E) describe the phenotypes indicated by each metric relative to
wt JR-CSF. The infectivity profile of each Env was independently repeated twice.
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as an increased infectivity at low levels of CD4 relative to
wt JR-CSF (compare blue and green bars in Figure 3C to A),
into a more complex interplay of both CD4 and CCR5
that supports the role of this mutation in facilitating CCR5
recognition.
In contrast, K421D exhibited inefficient entry at low
levels of CCR5, which is consistent with the known role of
this K421 bridging sheet residue in mediating coreceptor
interactions [44,45]. Interestingly, at high CCR5 levels (2
and 1 μM PonA), K421D responded more dramatically to
increasing levels of CD4 than wt JR-CSF (Figure 3C). These
phenotypic properties are reflected by a decrease in θ (30.9°
to 23.1° for wt JR-CSF and K421D, respectively), and a con-
comitant increase in Δ (50.6 to 69.2 for wt and K421D, re-
spectively) (Figure 3D and E). Just as an increase in θindicates that the S142N and E153G Envs are more respon-
sive to changes in levels of CCR5 expression when com-
pared to wt JR-CSF, a decrease in θ indicates that the
K421D Env is more responsive to changes in CD4 levels.
The increase in amplitude for K421D is apparent because
the differential magnitude of response is markedly greater
for K421D at the highest CCR5 and CD4 levels, which is
related to the relative lack of infectivity response at low
CD4/CCR5 levels. Recall that the amplitude measures the
“steepness” of the steepest direction along the surface function
F(x,y) used to fit the infectivity data (Figure 2, box). Overall,
the mean infectivity (M) for K421D was only moderately
decreased compared to wt JR-CSF (16.5 vs 20.1, Figure 3D
and E). This likely reflects a balance between the lack of
infectivity observed at low CD4/CCR5 levels, and the com-
pensatory increase in the magnitude of K421D’s infectivity
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ively, reveal that high levels of CD4/CCR5 may compensate
for the inefficient entry exhibited by the K421D mutation at
low CCR5 levels. A summary of these metric comparisons
and their meaning is included next to Figure 3E.
Affinofile infectivity profile and metrics reflect biologically
relevant differences in T-cell tropism
To determine how these Affinofile metrics reflect the abil-
ity of a viral Env to infect primary CD4+ T-cells, we in-


































Figure 4 Sensitivity vector metrics reflect biologically relevant differe
luciferase reporter pseudotypes bearing wt, S142N, or K421D JR-CSF envelo
(except for VSV-G) could be inhibited by maraviroc (>95%). Error bars repre
(PE-Cy7) and CD45RO (FITC) to identify the following T-cell subsets: Naïve (
Memory (TEM, CCR7- CD45RO+), and Effector Memory RA (TEMRA, CCR7- CD
indicated pseudotyped viruses at an MOI of 20 (as titered on Ghost-R5 cell
cytometry. (C) Infected cells were identified by intracellular p24 staining us
is shown in grey density plot, while infected p24+ cells are overlaid as the red
All infections could be inhibited by maraviroc (>90%). Data shown here is a reviruses bearing wt JR-CSF, S142N or the K421D Env mu-
tants. Figure 4A shows that the S142N virus infected
PBMCs better than wt JR-CSF while the K421D virus ex-
hibited the lowest level of infection. This pattern reflected
the θ and M metrics of the respective viruses, as the limit-
ing parameter on primary CD4+ T-cells are the levels of
CCR5 (low), not CD4 (high).
Next, we infected CD3/CD28 stimulated CD4+ T-cells
with wt JR-CSF, S142N or the K421D Env pseudotyped
virus, and assessed the infection of the indicated CD4+
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infection. The overall levels of infection, as determined by
the percentage of p24+ cells, were consistent with the lu-
ciferase reporter results observed in Figure 4A, with
S142N infecting the greatest proportion of cells and
K421D the lowest (Figure 4C). In most cases, the majority
of p24+ cells were CD4+ T-central memory cells (TCM,
CCR7 + CD45RO+), with the remainder comprising the
effector memory subset (TEM, CCR7-CD45RO+) or the
naïve T-cell subset (Tnaive, CCR7 + CD45RO-) (Figure 4D).
It is unclear whether the small number of p24+ cells
found in CD4+ T-effector RA + cells (TEMRA, CCR7-
CD45RO-) represents a reproducibly infectable population
since CD4+ TEMRA cells are thought to be non-permissive
for R5 virus infection [46].
Interestingly, the S142N mutant demonstrated not only
an increase in overall infectivity, but also an altered pattern
of cellular tropism. Compared to wt JR-CSF, the S142N
mutant infected almost 4-fold more naïve T-cells (25.9% vs
6.8%) and 2-fold more TEM cells (21.8% vs 12.4%). As a
consequence, S142N infected fewer TCM cells compared to
wt JR-CSF (48.5% vs 79.9%) (Figure 4D). Although K421D
infected fewer CD4+ T-cells, the CD4+ T-cell subset distri-
bution resembled that of wt JR-CSF infection. Thus, the dif-
ferential ability to use CCR5 as quantified by the GGR
Affinofile assay is reflected in the differential ability of the
wt and mutant JR-CSF Envs (S142N) to infect CD4+ T-cell
subsets where relatively high and uniform CD4 expression
is coupled to relatively low and variable CCR5 expression
[20,46]. Our results indicate that the distinct entry efficien-
cies quantified by our GGR Affinofile system reflect the
biologically relevant contributions of CD4 and CCR5 usage
to primary CD4+ T-cell subset tropism.
Affinofile metrics reveal differences in CD4/CCR5 usage
efficiencies between chronic and transmitter/founder
derived Envs
An accumulating body of evidence indicates that the major-
ity of primary infections are established by a single viral
clone [47-49]. To discern whether relevant differences in
entry efficiencies exist between T/F and chronic Envs, we
used the GGR Affinofile system to examine the infectivity
of T/F Envs (isolated from acutely infected Feinberg stage
II or III patients) [50], and compared their Affinofile GGR
metrics (θ, Δ, M) with those from a standard panel of
chronic Envs. The specific clones used are indicated in [see
Additional file 2: Table S1]. The infectivity of each T/F and
chronic Env was examined at 25 distinct CD4/CCR5 ex-
pression levels [see Additional file 3: Figure S2A-B], and
their infectivity metrics (Figure 5A-C) were obtained via
VERSA as described in methods.
Figure 5A shows that T/F Envs have a median θ that
is significantly lower than that of chronic Envs (15° vs
25°, p = 0.0003), and that this lower θ was associated with alower Δ (vector amplitude) (Figure 5C). This correlation in-
dicates a diminished responsiveness (lower Δ) that is
weighted toward CD4 (lower θ), meaning T/F Envs take ad-
vantage of increases in CD4 expression less efficiently than
Chronic Envs. The decreased responsiveness to CD4 is
most evident at lower, more physiological levels of CCR5
expression, illustrated in Figure 5D and E. The wedge plot
in Figure 5F summarizes the distinct T/F and chronic Env
phenotypic differences in and observed within the cohort
of subtype B Envs examined. Finally, the 2-D contour plots
of the averaged infectivity between T/F and chronic Envs
across the spectrum of CD4/CCR5 expression levels cor-
roborate the differences indicated by their infectivity met-
rics: that at low to moderate levels of CCR5 (0–0.5 μM
Pon), even the highest level of CD4 allowed only moderate
entry levels (40-60%) for the T/F Envs (Figure 5G, compare
upper right quadrants). This phenotype is consistent with
the observation that T/F Envs, despite being universally
CCR5-using, are almost always primary T-cell tropic (high
CD4/low CCR5) and not macrophage-tropic (low CD4/
high CCR5) [30]. We confirmed that all six of these R5 T/
F Envs are indeed non-macrophage-tropic (Figure 5H).
Affinofile metrics reveal that HIV-1 Envs exhibit subtype-
specific differences in CD4/CCR5 usage efficiencies
We next used the GGR Affinofile cells to characterize a pa-
nel of 28 subtype A, B, C and D Envs [see Additional file 4:
Table S2]. As might be expected from a diverse panel of
subtype Envs, there was a high degree of intra- and inter-
subtype variability in all three metrics (Figure 6A). An add-
itional figure shows the infectivity profile for each subtype
Env examined [see Additional file 5: Figure S3]. Despite this
variability, significant differences in CD4/CCR5 usage pat-
terns between HIV-1 subtypes can be appreciated. For ex-
ample, subtype C Envs had the highest θ and M values
(Figure 6A), indicating that this subtype, as a group, used
CCR5 more efficiently than Envs from other HIV-1 sub-
types. The aggregate infectivity data confirms that subtype
C Envs do, indeed, achieve a higher level of infection in re-
sponse to increasing CCR5 levels, especially when CD4
levels are limiting (Figure 6B, compare the lower left
quadrants). Interestingly, when CCR5 levels are low, sub-
type C Envs exhibited markedly reduced levels of infectiv-
ity compared to Envs from other HIV-1 subtypes, even at
the highest CD4 levels (Figure 6B, compare upper right
quadrants). Although this subtle nuance is not captured in
Δ, infectivity profiles serve as an alternative method that
adds depth to the existing algorithm. Finally, Envs from
both HIV-1 subtypes A and C have significantly higher M
values than subtype B Envs (Figure 6A). The polar plot in
Figure 6C shows that subtype C envelopes can be clearly
distinguished from other subtype envelopes based on their
and metrics even if the amplitudes (Δ) do not differ sig-
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Figure 5 Sensitivity vector metrics reveal differences in CD4/CCR5 usage efficiencies between Transmitter/Founder (T/F) and chronic
envelopes. Normalized infection data using T/F and chronic Env clones were analyzed using VERSA. (A) Vector angle, (θ), (B) mean infectivity
(M), and (C) vector amplitude (Δ) values were obtained for each Env clone. Each Env was profiled twice, in triplicate, across 25 combinations of
CD4/CCR5 expression. Average metrics of 6 individuals from each group (T/F or chronic, N=12) are shown, each group consisting of 900 data
points. The median value of each metric for the T/F and chronic Env cohorts is marked by a line. p values were generated by the non- parametric
unpaired t test (***p = 0.0003; *p = 0.05). (D and E) The normalized infectivity for the chronic (blue line) and T/F envelopes (red line) are averaged, and
compared as a group at (D) low and (E) high levels of CCR5 expression, across varying levels of CD4 as indicated. (F) Wedge plot of the average angle
and amplitude (+/− S.D.) obtained for T/F (dark grey) versus chronic envelopes (light grey). (G) The infectivity profile of individual T/F and chronic Envs
(from Additional file 5: Figure S3) were averaged to form their respective group profile. 2-D contour plots representing the averaged infectivity profiles
of T/F and chronic envelopes are shown. (H) T/F Envs and macrophage tropic (YU2, ADA) and non-macrophage tropic (JRCSF) R5 Envs were used to
produce Env pseudotyped luciferase reporter viruses, which were subsequently titrated on JC53 cells. Monocyte derived macrophages were
inoculated with equivalent infectious units of each reporter virus, and luciferase activity measured in cell lysates at 72hrs post infection. Results of
infection in 3 independent donors are shown. Results are means of triplicate wells, and error bars represent standard deviations.
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neutralizing antibodies also results in reduced entry
efficiency
Recent technological advancements have resulted in the
cloning and characterization of numerous broadly neu-
tralizing antibodies (BNabs) with increased potency and
breath of coverage compared to the “classical” BNAbs
such as b12, 2G12 and 2F5. PG9/PG16 and VRC01 repre-
sent two of the major classes of these “next generation”
BNabs with non-overlapping epitopes [51-53]. Despite the
breath and potency of these BNAbs, single point mutations,
N160K and N279/280A, can confer resistance to PG9/
PG16 and VRC01, respectively [51,53]. N160 and N279/
280 are highly conserved residues across HIV-1 subtypes
[See Additional file 6: Figure S4A], which suggest that
these residues are under selective pressure.
To determine potential entry efficiency consequences
related to these BNab resistance mutations we gener-
ated resistant N160K and N279/280A mutants in 24
Envs representing subtypes A through D, and examined
their CD4/CCR5 entry efficiencies using the GGR Affi-
nofile system. Figure 7A, B and C, shows the mean in-
fectivity profiles for wt Envs (n = 12, 3 each from
subtype A-D), and their respective isogenic N160K, and
N279/280A mutants, each Env examined across 25 dis-
tinct CD4/CCR5 expression levels. An additional figure
shows the individual infectivity profile for all 36 Envs
examined [see Additional file 6: Figure S4]. The PG9/
PG16 (N160K) and VRC01 (N279/280A) resistance
mutations reduce the efficiency of entry; both requiring
higher levels of CD4 and CCR5 to achieve similar levels
of infection as their wt counterparts. This can be appre-
ciated by comparing the CD4/CCR5 expression level
combinations that give rise to low levels of infection
(green areas), or conversely, those that give rise to the
highest level of infection (red areas), between the wt
and mutant Envs (Figure 7A-C). This reduced entry ef-
ficiency phenotype across all subtypes tested is quanti-
tatively reflected in the values, where the average M for
PG9/PG16 and VRC01 resistant mutants is lower thanthat of their wt counterparts (Figure 7D and E). However,
due to marked variability when comparing across all HIV-1
subtypes, only the difference between VRC01 resistance
mutants and wt reached significance (p = 0.007). Our re-
sults suggest that resistance to BNAbs comes at the cost
of reduced HIV-1 entry efficiency, and provides one
functional explanation for the high conservation of
these residues across HIV-1 subtypes. Both these rea-
sons bode well for vaccine design that will elicit these
kinds of BNAbs.
Discussion
The Affinofle system and associated VERSA metrics
have provided investigators a more quantitative method
to characterize viral entry efficiency as a function of
CD4 and CCR5 expression. Quantitative comparisons of
these three VERSA metrics—Mean infectivity (M), Vec-
tor Angle (θ) and Amplitude (Δ)—have facilitated our
understanding of how CD4/CCR5 usage efficiencies cor-
respond to distinct Env phenotypes associated with re-
sistance to CCR5-inhibitors, and the myriad of in vitro
or in vivo selective pressures that result in differential or
altered cell tropism [28,34,36,37,39,54-56].
Efficiency of CD4/CCR5 usage and T cell subset tropism
A critical feature of our GGR Affinofile system is the abil-
ity to distill the aggregate entry phenotype of Env into
three metrics. Here, we demonstrate that these VERSA
metrics reflect biologically relevant phenotypes for wt JR-
CSF Env, and two point mutants (S142N and K421D)
known to modulate its affinity for CCR5, and the complex
interplay of CD4 and CCR5 usage associated with muta-
tions that affect conformational transitions (E153G). Spe-
cifically, S142N, which had larger θ and M values relative
to wt JR-CSF, also infected total PMBCs better. This in-
crease infectivity may be due to an expanded CD4+ T-cell
subset tropism as S142N pseudotyped virions infected a
larger portion of naïve T-cells relative to their wild-type
counterparts (Figure 4C, 25.9% vs 6.8%). Intriguingly,
naïve T-cells have undetectable levels of CCR5 by FACS
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Figure 6 HIV envelopes exhibit subtype-specific differences in CD4/CCR5 usage efficiencies. (A) Normalized infection data from each
subtype A, B, C and D envelope clones (n = 28) were analyzed by VERSA. The vector metrics were averaged for at least two independent
infections (with a variance <5%) for each envelope in each subtype group. Vector angle (θ), mean infectivity (M), and vector amplitude (Δ) values
for each envelope are shown as grouped by subtypes. P values were generated by the non- parametric unpaired t test (p*** < 0.005, **p < 0.05).
B) 2-D contour plots of the average infectivity profile for each subtype, generated and color coded as in Figure 4G. The colored dashed square
boxes compare the infectivity differences noted between subtype C (blue) Envs and others (red) in the lower left (LL) and upper right (UR)
quadrants. Each Env clone was independently profiled twice. (C) Polar plot of the averaged sensitivity vectors obtained from each subtype,
generated as in Figure 3E.
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Figure 7 Affinofile profiling reveals that resistance to broadly neutralizing antibodies (BNAbs) also results in reduced entry efficiency.
(A-C) N160K and N279/280A mutations were engineered into a random sample of 12 subtype A-D Envs. The resultant (PG9/PG16)R and (VRC01)R
resistant Envs were assayed for CD4 and CCR5 usage efficiency along with their parental BNAb sensitive Envs. GGR Affinofile profiling was
performed as previously described. 2-D contour plots of the averaged infectivity profiles for (A) WT, (B) (PG9/PG16)R, and (C) (VRC01)R Envs are
shown. The infectivity profile for the individual Envs are shown in supplementary Figure S5. Axes and color-codes are identical to previous
contour plots. (D-E) The median values and interquartile ranges of the Mean infectivity (M) are shown for (PG9/PG16)R or (VRC01)R resistant Envs
compared to their WT counterparts. P values calculated via a non-parametric paired t-test.
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lines (Molt 4 and SupT1) that the S142N Env virus is
known to infect in a CCR5-dependent manner [25]. Con-
versely, K421D, which had the smallest θ and M values,
also infected PBMCs with the least efficiency, and lacked
the expanded tropism seen with the S142N mutant.
Our GGR/Affinofile system can interrogate an Env
phenotype across a fuller fitness landscape than traditional
assays. The ability to evaluate infectivity across a broad
spectrum of CD4 and CCR5 expression levels underscores
the innate inter-dependence of CD4 and CCR5 levels in
the context of infection. For example, although the en-
hanced macrophage tropism of the E153G mutant was
originally attributed to increased CD4 binding affinity and
more efficient infection on cells expressing low levels of
CD4, our Affinofile assay describes an Env that is more re-
sponsive to changes in CCR5 than wt JR-CSF (θ = 38.3°
and 30.9° respectively, Figure 3E). Our results complement
and expand published results on E153G, and provide dir-
ect support for the proposed effect of E153G on V1/V2
loop flexibility, which can affect exposure of both the CD4
and CCR5 binding sites. The latest structural evidence
also supports such a model [59].What is the utility of being able to quantify the effi-
ciency of CD4/CCR5 usage through a set of standardized
metrics? For S142N, the ability to use lower levels of CD4
and CCR5 for entry correlates with its expanded tropism
for naïve CD4+ T cells. HIV-1 preferentially infects mem-
ory, rather than naïve CD4+ T cells [60-62]. However, loss
of naïve T-cells is also clearly associated with immune sys-
tem decline and disease progression, but is thought to be
due to secondary factors such as lymph node fibrosis,
which destroys the regenerative niche required for main-
taining naïve T-cells [63,64]. To our knowledge, the infec-
tion of naïve T-cells in lymph nodes of late stage patients
have not been directly examined. Since late stage R5 iso-
lates are also more efficient at using low levels of CD4 and
CCR5 for entry [12,65], it is possible that infection of
naïve T-cells by late stage R5 Envs might contribute to the
diminishment seen. Currently, macrophage-tropism is
widely used as a surrogate measure for R5 Envs that can
use low levels of CD4 and/or CCR5 for entry [66], but it is
not clear whether macrophage-tropic Envs also have an
expanded tropism for naïve CD4+ T-cells. Use of our
GGR Affinofile system and VERSA metrics to characterize
extended panels of R5 macrophage-tropic and R5 non-
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portant issue related to R5 Env pathogenesis. Intriguingly,
even a binary read-out, such as an increased ability to in-
fect CD4low/CCR5high relative to CD4high/CCR5high Affi-
nofile cells, has been observed in CSF-derived R5 Envs
from a patient many months before the patient developed
HIV-1 associated dementia [67]. Thus, it would also be of
interest to determine the VERSA metrics of R5 Envs from
a broader array of longitudinal cohorts to evaluate
whether a certain pattern of VERSA metrics is predictive
of pathogenicity or disease progression.
T/F and chronic Envs
~70-80% of heterosexual or IV drug use HIV-1 trans-
mission cases are established by a single transmitted/
founder (T/F) virus clone [50,68-71]. Concerted efforts
have been made to discern genotypic and phenotypic dif-
ferences between T/F and chronic Envs, since such differ-
ences may inform vaccine design, shed light on the
biology of HIV-1 transmission and pathogenesis, or facili-
tate development of strategies to prevent HIV-1 transmis-
sion [47,48]. While T/F Envs are enriched in genotypic
features such as an overall reduction in the number of po-
tential N-linked glycosylation sites (PNGS) [72], no unique
genetic signatures can be ascribed only to T/F Envs.
Phenotypic differences between T/F and chronic Envs also
appear subtle: no overt differences were found in multiple
assays such as entry/fusion efficiency into cells expressing
high or low levels of CD4/CCR5, infection of CD4+ T-cell
subsets, dendritic cell mediated trans-infection, and sensi-
tivity to entry inhibitors [73-77]. However, moderate in-
creases in sensitivity to neutralization by the CD4 binding
site antibody b12, and more marked resistance to sCD4
inhibition, have been reported for some cohorts of subtype
B T/F Envs relative to chronic Envs [75,76].
Our Affinofile profiling of a small panel of subtype B T/
F and chronic Envs reveals moderate but significant differ-
ences in the CD4/CCR5 usage efficiencies. The differences
are subtle, but the combination of θ and Δ clearly distin-
guishes the T/F Envs from the chronic Envs (Figure 5F).
These data also indicate that T/F Envs are less efficient at
using CD4, as a diminished responsiveness (lower Δ) is as-
sociated with CD4 (lower θ) without a significant change
in overall infectivity (M) (Figures 5A, B and C). The im-
plied decrease in CD4 usage efficiency exhibited by the T/
F Envs in our study is consistent with the aforementioned
cohort of T/F Envs with increased resistance to sCD4
neutralization [76]. However, sensitivities to sCD4 or b12
neutralization are surrogate markers for CD4 utilization,
and neither directly measures the true entry phenotype of
a virus with regards to CD4/CCR5 usage efficiency. sCD4
sensitivity does not always correlate with gp120-CD4
binding affinity ([78] and references therein), and b12
neutralization can be affected by epitope changes thatdon’t affect CD4 binding [79]. For example, T/F Envs are
enriched for the loss of a particular N-glycan site, medi-
ated by not having a Thr at position 415 (T415X), that al-
lows better access to key b12 binding residues at positions
417–419 [72]. Thus, the increased sensitivity to b12
neutralization may be associated with a genetic signature
(T415X) enriched in T/F Envs, rather than being a general
property of T/F Envs per se. In our cohort, there is no ob-
vious relationship with sensitivity to b12 or sCD4
neutralization even though all but one T/F Env has the
T415X signature [see Additional file 2: Table S1]. Yet, in-
fectivity profiling across the full spectrum of CD4/CCR5
expression levels and VERSA metrics were able to reveal
differences in entry phenotypes between T/F and chronic
Envs. Clearly, our findings need to be extended by examin-
ation of larger groups. However, recent evidence suggests
that T/F envs and chronic Envs can differ in their ability to
use the maraviroc bound form of CCR5, but this phenotype
is more obviously revealed only on CD4high/CCR5high Affi-
nofile cells [80]. The ability to use the MVC-bound form of
CCR5 in this case is likely a surrogate marker for an ex-
panded promiscuity in the use of CCR5 conformations.
These results are consistent with our current findings and
suggest that the full Affinofile profiling may have the
requisite sensitivity to reveal subtle but real differences in
Env phenotypes related to HIV-1 transmission.
The pattern of responses to CD4 and CCR5 observed
using the Affinofile system and their correlation to infection
on primary cells with different CD4 and CCR5 expression
levels are naturally sensitive to alternate CCR5 conformations
and post-translational modifications [81-89] that may or may
not support entry. To achieve the most representative meas-
ure of CCR5 in the context of HIV entry, expression is quan-
tified in terms of cell-surface epitopes specifically recognized
by the broadly and potently neutralizing CCR5 Mab 2D7, a
biologically relevant, surrogate measure of the majority of
CCR5 that is accessible and functional as bona fide entry
coreceptors [90]. However, we cannot rule out that some
Envs can use qualitatively different conformations of CCR5
that are not represented by 2D7 antibody binding sites.
Subtype Env specific differences
Subtype C viruses, in pure or recombinant forms, comprise
the majority of HIV-1 infections worldwide, and are associ-
ated with heterosexual transmission. Subtype Envs do ex-
hibit phenotypic differences as evidenced by a significant
correlation between CCR5 and FPRL1 usage for subtype A
and C Envs, and between CCR5 and CCR3 usage only for
subtype B Envs [91,92]. These differences in alternate core-
ceptor usage in highly permissive NP2/CD4/CoR cells likely
reflects the different evolutionary histories of the subtype
Envs, and is more apt to be a surrogate marker for the effi-
ciency of CCR5 usage or the use of a specific conformation
of CCR5.
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in utero than subtype A or D Envs [93]. Thus, it seems
reasonable to intuit that subtype C Envs are more efficient
in cell entry and/or transmission. However, in vitro and
ex vivo assays indicate that viruses bearing subtype C Envs
are invariably outcompeted by other subtype Envs in
PBMC outgrowth assays [94-96]. This decrease in replica-
tive fitness presents an explanatory conundrum that may
be illuminated by our Affinofile data. Our GGR Affinofile
profiling results indicate that the average subtype C Env
used CCR5 more efficiently than the other subtype Envs,
but this was only true at low to moderate levels of CD4
(Figure 6B, compare lower left quadrants). Future refine-
ments of the metric algorithm can provide more detail to
these subtle nuances. At high levels of CD4 but lower
(more physiologic) levels of CCR5 such as would be
present on activated PBMCs (Figure 6B, compare upper
right quadrants), subtype C Envs are less efficient at entry.
The difference in entry efficiencies between subtype C and
the other subtype Envs, reflected in the UR and LL quad-
rants of their infectivity profile (Figure 6B), might provide
an explanatory framework that accounts for both the de-
creased replicative fitness observed in vitro (on activated
PBMCs), and the notion that subtype C Envs must be
more efficient at entry and/or transmission at some level.
The VERSA metrics and infectivity profiles in Figure 6
quantify a genuine phenotypic difference between subtype
C and other subtype Envs, and can serve as a reference
point for future studies into their physiological correlates.
Despite the small number of Envs examined (n = 28, 7 for
each subtype), these are well-characterized reference sub-
type Envs, chosen carefully to represent acute/early infec-
tion isolates, so as to compare the Env phenotypes that
might be specific to each subtype before disease stage-
specific selective pressures come into play [see Additional
file 4: Table S2].
BNAb resistance mutations
Our Affinofile profiling suggests that mutations in Env
that confer resistance to at least two BNAbs come at a fit-
ness cost. This is perhaps not surprising since the mutated
residues N160 and N279/280 are themselves highly con-
served amongst HIV-1 subtypes suggesting that selective
pressures are at play. Nevertheless, we engineered muta-
tions into 12 Envs from 4 different subtypes, and observed
a general trend that N279/280A (VRC01)R mutations, and
to a lesser extent, the N160K (PG9/PG16)R mutations de-
crease the mean infectivity without a significant impact on
the other two VERSA metrics. While the (VRC01)R muta-
tion near the CD4bs was likely to affect entry efficiency, it
was not clear that the (PG9/PG16)R mutation would. In-
deed, the impact on entry efficiency is much greater for
the (VRC01)R mutation compared to the (PG9/PG16)R. It
remains to be seen if resistant mutations to the latestgeneration of BNAbs all come at a fitness cost or whether
they are epitope dependent. We recognize that our results
regarding the impact of BNAb resistant mutations on
entry efficiency need to be confirmed and expanded with
a larger set of mutants and antibodies. Our GGR Affinofile
system provides an appropriately high throughput meth-
odology to facilitate such future studies. The results from
these further studies might inform the engineering of the
most appropriate immunogen that will elicit the BNAbs
that will best constraint the development of resistance.
Conclusions
In sum, Affinofile profiling not only interrogates the func-
tional plasticity of HIV-1 Env in response to a spectrum of
CD4 and CCR5 expression levels, it provides and distills
the multi-dimensional data that captures this functional
plasticity. Thus, Affinofile profiling may be a more sensitive
method for discerning subtle but real differences in entry
phenotypes that are not detected by other standard assays
for evaluating CD4/CCR5 usage efficiency. A database of
carefully curated VERSA metrics will help standardize the
phenotypic characteristics of Envs from multiple cohorts
and facilitate future studies into pathophysiology associated
with Env phenotypes. We are currently creating a panel of
GGR Affinofile cell lines that express alternate coreceptors
as well as hybrid and mutant CCR5 that will help extend
and refine such studies.
Methods
Virus production
Envelopes and the SG3Δenv vector were obtained through
the NIH AIDS and Research and Reference Reagent Pro-
gram. Details and provenance of all envelopes used are
given in Additional file 2: Table S1 and Additional file 4:
Table S2. Pseudovirons were generated by cotransfection
of 293T cells with Env-deleted SG3Δenv vector and Env
expressing vector at a 3:1 ratio with Bioline Bio T transfec-
tion reagent. 72 hours post transfection, viral supernatant
was collected, clarified by low speed centrifugation and
stored at −80°C. The number of infectious virus particles
was determined by titration on Ghost HI-R5 cells, as de-
scribed previously [97].
CD4 and CCR5 cell surface expression
CD4 and CCR5 surface expression levels were determined
by quantitative flow cytometry (qFACS) as described pre-
viously [34,39].
GGR vector cloning
pNL-GFP-RRE was obtained through the NIH AIDS Re-
search and Reference Reagent Program [40,41]. pNL-
GFP-RRE was digested with SacI and SalI. The Gaussia
luciferase gene was PCR amplified from pCMV-Gluc
(Promega). The PCR product was digested with SacI and
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RRE vector to form pNL-GGR.
GGR virus production
GGR-expressing lentiviral transducing viruses were pro-
duced by cotransfection of 293T cells with pNL-GGR
vector, pCMVΔR8.2, and pVSV-G at a ratio of 10:10:1,
respectively, using the calcium phosphate method. Two
days post transfection the viral supernatant was col-
lected, clarified by low speed centrifugation, and filtered
through a .45μM filter. Viral supernatant was then con-
centrated by ultracentrifugation at 32,000 x g for 90 mi-
nutes and stored at -80C.
GGR single cell cloning
Affinofile cells were seeded into a 48 well plate at 5 X 104
per well. 24 hours later cells were infected with 1 μg (p24
equivalents) of VSV-G pseudotyped GGR virus. Infected
cells were then spinoculated for 2 hours at 37 degrees and
770 x g. Cells were washed once with PBS and replenished
with fresh D10/B media. Cells were allowed to grow in a
10cm culture dish for three weeks, by splitting and replen-
ishing media every 2–3 days. Single cell clones were then
obtained by limiting dilution into 96-well plates. Single cell
clones were passaged for three weeks, and clones with
stable integration of the pNL-GGR vector were screened
for optimal signal to noise ratio of Gaussia luciferase ac-
tivity in the supernatant upon infection with JR-CSF virus.
Selected clones were then screened for ones that still
maintained a robust CD4 and CCR5 inducible response to
doxycycline and ponasterone A.
T cell infection
Leukopacks from healthy uninfected donors were ob-
tained from the virology core at the UCLA CFAR. For
purification of CD4+ T-cells, buffy coats containing per-
ipheral blood mononuclear cells (PBMC) were first
Ficoll-purified, and CD8+ T cells were depleted using
Invitrogen CD8 Dynabeads. CD8 depleted PBMCs were
incubated in RPMI supplemented with IL-2, 20% FCS
and stimulated with CD3/CD28 coupled Dynabeads
(Invitrogen) for three days. Three days post-stimulation,
cells were washed twice and infected with indicated
virus. Infection was synchronized by spinoculation for 2
hours at 2,000 rpm (770x g) at 4°C. After spinoculation,
infectious media was replaced with fresh media. Three
days post infection cells were collected and stained for
T-cell subset markers CD4 (RPT-4), CD3 (OKT3), CCR7
(3D12) CD45RA (Hl100) (Ebiosciences), and intracellular
p24 (KC57, BD Pharmingen).
GGR affinofile assay
GGR Affinofile cells were seeded in a 96 well plate at 2 X
104 cells/well. Simultaneously, cell surface expression ofCD4 and CCR5 was induced with 0 to 4.0 ng/mL of Doxy-
cycline and/or 0 to 2 μM of Ponasterone A, respectively.
18hrs later the induction media was removed. Each well
of cells was then inoculated with HIV-1 at an MOI of
0.25, as determined on Ghost R5 cells. The cells were then
spinoculated (770 x g) for 2 hours at 37° C. Infectious
supernatant was then replaced with fresh D10 media
(DMEM with 10% FBS and 1% Pen/Strep). At the indi-
cated timepoints (hours post-infection) used in the various
assays, 10 μl of supernatant was combined with 10 μl of
substrate detection buffer (SDB: 50mM Tris–HCl (pH
7.5), 20% glycerol, 0.1% TritonX-100, 10mM DTT). The
supernatant and SDB mix was assayed for Gaussia lucifer-
ase (GLuc) activity using Coelenterazine substrate in 96-
well black plates according to manufacturer’s instructions
(NEB, Ipswich, MA). GLuc-catalyzed bioluminescence
was detected on the TECAN Infinite® M1000 microplate
reader via luminescence scanning with an integration time
of 8 seconds. All test were done with mararviroc controls
to confirm exclusive CCR5 coreceptor usage.
Data analysis
The Affinofile infectivity metrics were derived from raw
or normalized data using the VERSA (Viral Entry Recep-
tor Sensitivity Analysis) computational platform as pre-
viously described [34]. The considerations for the use of
raw versus normalized data, and the limitations of each
have been extensively reviewed [39].
Additional files
Additional file 1: Figure S1. Isolates with different CD4 and CCR5
usage can be represented by distinct 3-D surface plots. GGR Affinofile
cells induced to express 25 different combinations of CD4 and CC5 were
infected with the (A) “CD4-independent” R5 SIV316, (B) R5X4 89.6, or (C)
X4 IIIB pseudotyped viruses. The SIV 316 infection profile indicated that
SIV 316 is much more sensitive to changes in CCR5 levels, and is relatively
insensitive to varying CD4 levels. Conversely, the HIV IIIB infectivity profile
indicated a phenotype that was dependent on changes in CD4, but
was relatively insensitive to changes in CCR5. This phenotype can be
attributed to the use of low levels of CXCR4 present on the HEK293 cells,
the parental derivative of GGR Affinofile cells. The 89.6 virus demonstrated
an infectivity profile that was equally sensitive to changes in CD4 and CCR5
levels. The distinct infectivity profiles for each Env demonstrated in A-C can
be mathematically transformed into the corresponding 3-D surface plots
shown in D-F. These three envelopes represent the diverse range of infectivity
profiles that can be demonstrated in GGR Affinofile cells. (G) A polar plot
representing the three metrics describing the infectivity profiles of the three
viruses is shown. SIV316 has a vector angle closest to 90 degrees
indicating a greater infective response to CCR5 expression and reflecting the
CD4-independence of this Env. Conversely, HIV IIIB has a vector angle closest
to zero degrees, endorsing an X4 tropism that is manifested as CCR5
independence. 89.6 has a vector angle of ~45 degrees indicating that it is
equally sensitive to changes in CD4 and CCR5 levels. Each circle represents
one independent experiment profiling infectivity across 25 distinct CD4/
CCR5 expression levels.
Additional file 2: Table S1. List of T/F and chronic envelopes.
Additional file 3: Figure S2. Infectivity profiles of Chronic and T/F
Envelopes. The infectivity profile for individual chronic (A) and T/F (B)
derived envelopes across a spectrum of CD4 and CCR5 expression levels
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One representative experiment out of two is shown. Each infectivity data
point was performed in triplicate. The contour plots are arranged from
highest to lowest mean infectivity (M), from left to right. (C) T/F Envs and
macrophage tropic (YU2, ADA) and non-macrophage tropic (JRCSF) R5
Envs were used to produce Env pseudotyped luciferase reporter viruses,
which were subsequently titrated on JC53 cells. Monocyte derived
macrophages were inoculated with equivalent infectious units of each
reporter virus, and luciferase activity measured in cell lysates at 72hrs post
infection. Results of infection in 3 independent donors are shown. Results
are means of triplicate wells, and error bars represent standard deviations.
Additional file 4: Table S2. List of subtype envelopes.
Additional file 5: Figure S3. Infectivity profiles of Subtype A-D Envelopes.
The infectivity profile for indivudal Subtype A, Subtype B, Subtype C and
Subtype D derived Envs (A-D, respectively) across a spectrum of CD4 and
CCR5 expression levels were generated and plotted as described in the
Materials and Methods. One representative experiment out of at least two
is shown. The contour plots are arranged from highest to lowest mean
infectivity (M), from left to right.
Additional file 6: Figure S4. Infectivity profiles of (PG9/PG16)R or
(VRC01)R Envs. (A) Consensus and/or predicted ancestral Env sequences
from subtypes A-D were obtained from the Los Alamos HIV sequence
database (http://www.hiv.lanl.gov), and the amino acid sequences from
the relevant regions aligned. Arrows highlight location of conserved residues
where single point mutations were engineered to confer PG9/16 (N160K)
or VRC01 (N279/280A) resistance. (B-D) 2-D contour plots of the infectivity
profile for individual Envs are shown for the wild-type parental WT (A), and
the corresponding N160K (B), and N279/280A (C) mutants. Subtype specific
Envs (A1-3, B1-3, C1-3) refer to the Env clones listed in Additional file 4:
Table S2. Axes and color-codes are identical to previous contour plots.
Contour plots are ordered based on the M values of the parent Env (highest
to lowest, from left to right).
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